Details
Stereochemistry | RACEMIC |
Molecular Formula | C27H29N3O2.ClH |
Molecular Weight | 463.999 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4
InChI
InChIKey=MOROBKPIULFQDC-UHFFFAOYSA-N
InChI=1S/C27H29N3O2.ClH/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30;/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C27H29N3O2 |
Molecular Weight | 427.5381 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/818f4654ed39a1c147d1e51a00ffb4cb.htmlCurator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800001739
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33180
Sources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/818f4654ed39a1c147d1e51a00ffb4cb.html
Curator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800001739
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33180
Mozavaptan hydrochloride was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 26, 2006. It was developed and marketed as Physuline® by Otsuka in Japan. Mozavaptan hydrochloride is a vasopressin receptor antagonist. It is indicated for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Physuline® is available as film-coated tablet for oral use, containing 30 mg of Mozavaptan hydrochloride. The recommended dose is one tablet (30 mg) once daily after a meal.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111456 Sources: http://www.selleckchem.com/products/mozavaptan.html |
1.2 µM [IC50] | ||
Target ID: CHEMBL1790 Sources: http://adisinsight.springer.com/drugs/800001739 |
14.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PHYSULINE Approved UsePHYSULINE is used for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective. Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. | 1992 Apr |
|
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. | 1997 Oct |
|
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. | 1998 Nov 6 |
|
Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260. | 2008 |
Patents
Sample Use Guides
The recommended dose is one tablet (30 mg) once daily after a meal.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8199714
Mozavaptan caused a concentration-dependent displacement of the selective AVP V2 receptor antagonist radioligand, [3H]desGly-NH2(9)[d(CH2)5, D-Ile2,Ile4]AVP from V2 receptors in rat kidney medulla membranes. The concentration of Mozavaptan that displaced 50% of specific AVP binding (IC50) was 20 +/- 2 nmol/l for renal V2 receptors.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:50:38 GMT 2023
by
admin
on
Sat Dec 16 05:50:38 GMT 2023
|
Record UNII |
F39AR1YW1O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2180
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C132047
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
636389
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
SUB90651
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
DTXSID90930125
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
F39AR1YW1O
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
138470-70-9
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
100000141041
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY | |||
|
m11874
Created by
admin on Sat Dec 16 05:50:38 GMT 2023 , Edited by admin on Sat Dec 16 05:50:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|